Facebook
Twitter
LinkedIn
ForwardGastrointestinal
Upper GI
The management of upper GI cancers remains complex, multidisciplinary, and rapidly changing. In this session, we will review the current data from randomized trials that have affected standard of care in upper GI cancers.
Lower GI
This session will outline the current standard of care options and new data regarding the treatment of lower gastrointestinal malignancies. First we will discuss the treatment of locally advanced rectal cancer focusing on the role of radiation in the multidisciplinary treatment of this disease. Data from randomized trials presented at ASCO 2020 will be highlighted as well the ASTRO clinical practice guidelines for rectal cancer published in January/February 2021. Special topics of clinical interest will be discussed including selective omission of radiation therapy for low risk patients and non-operative management for patients with a complete clinical response after radiation. Finally, we will discuss the role of chemoradiation in the definitive treatment of anal squamous cell carcinoma as well as the current cooperative group trials in this space.
Target Audience
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Identify the current standard(s) of care for esophagogastric cancer.
- Describe the changing role of radiation in pancreatic cancer.
- Identify current concepts in primary and secondary liver tumors and future directions.
- Identify, discuss and implement appropriate radiation options for a patient with locally advanced rectal adenocarcinoma.
- Describe and discuss controversial topics such as omission of surgery and omission of radiation for patients with locally advanced rectal adenocarcinoma
- Identify standard of care chemoradiation for patients with anal squamous cell carcinoma.
Theodore Hong, MD is employed by Massachusetts General Hospital and has research grants with AstraZeneca, Bristol-Myers Squibb, IntraOp, Taiho and Tesarao. He is also a consultant with Synthetic Biologics and is on the advisory board of Merck.
Emma Holiday, MD is employed by MD Anderson Cancer Center and receives research grants from Merck.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.